The Effects of Anxiety and Depression on Outcomes in Hematologic Malignancies: A Systematic Review and Meta-Analysis

1

Hematologic malignancies account for 1.3 million new cancer diagnoses and approximately 730,000 deaths globally in 2022.
2

Depression and anxiety are prevalent in cancer patients, with rates of 31.3% and 32.5%, respectively, and 20-30% in those with hematologic malignancies.
3

Patients with hematologic malignancies have a 6.7-fold increased risk of developing depression compared to the general population.
4

Anxiety and depression negatively impact survival and treatment adherence in hematologic malignancy patients, particularly in acute myeloid leukemia.
5

A systematic review and meta-analysis is necessary to clarify the effects of anxiety and depression on treatment outcomes in hematologic malignancies.

Bmc Cancer

by Dorsa Salabat, Samaneh Toutounchian, Danyal Salabat, Armin Babaei, Mahda Malekshahi, Maryam Barkhordar, Zahra Salehi
December 22, 2025

1